Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Isosorbide dinitrate/hydralazine"'
Autor:
Simon W. Lam, Mohamed Amar, Kathleen D. Faulkenberg, J. Bradley Williams, Antonio L. Perez, W.H. Wilson Tang
Publikováno v:
Journal of Cardiac Failure. 27:1053-1060
Background The role of oral vasodilators in the management of acute decompensated heart failure (ADHF) is not clearly defined. We evaluated the use of captopril vs hydralazine-isosorbide dinitrate (H-ISDN) in the transition from sodium nitroprusside
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dc89a01f4504b95ac42a2b80304402d
https://doi.org/10.1016/j.cardfail.2021.05.007
https://doi.org/10.1016/j.cardfail.2021.05.007
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S202-S203
Purpose The combination of isosorbide dinitrate/hydralazine (ISDN/HYD) offers direct arterial and venous vasodilation without adversely affecting renal function. It is used as an adjunct to standard heart failure therapies in adults with reduced ejec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95ab0fea0eb473e1a57a86346204a512
https://doi.org/10.1016/j.healun.2021.01.587
https://doi.org/10.1016/j.healun.2021.01.587
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
N. Richardson, B. Hong, Erin L. Albers, Yuk M. Law, N. Musa, Mariska Kemna, Joshua M. Friedland-Little, R. Mazor
Publikováno v:
The Journal of Heart and Lung Transplantation. 37:S390
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::140c364394fe81160c01d229ee162a01
https://doi.org/10.1016/j.healun.2018.01.1003
https://doi.org/10.1016/j.healun.2018.01.1003
Publikováno v:
Hypertension. 54:583-590
Hypertension-induced diastolic heart failure accounts for a large proportion of all heart failure presentations. Hypertension also induces left ventricular (LV) hypertrophy. Fixed-dose isosorbide dinitrate/hydralazine (HISDN) decreased mortality in h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::093231bd7ffc1d3ec91cc864d5deb814
https://doi.org/10.1161/hypertensionaha.109.134932
https://doi.org/10.1161/hypertensionaha.109.134932
Autor:
Joseph A. Franciosa, W. Tad Archambault, Michael L. Sabolinski, Clyde W. Yancy, Manuel Worcel, Jalal K. Ghali, Virginia M. Braman
Publikováno v:
The American Journal of Cardiology. 100:684-689
The benefits of fixed-dose combination isosorbide dinitrate plus hydralazine (ID/H) in African-Americans with heart failure (HF) were established by the African-American Heart Failure Trial (A-HeFT), which was terminated early because of a significan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::335581da93e2445cc11465f16434c78c
https://doi.org/10.1016/j.amjcard.2007.03.086
https://doi.org/10.1016/j.amjcard.2007.03.086
Autor:
Anne L. Taylor, Monica Colvin-Adams
Publikováno v:
Cleveland Clinic Journal of Medicine. 74:227-234
The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5ab18256408adcf79a5c5734db8395
https://doi.org/10.3949/ccjm.74.3.227
https://doi.org/10.3949/ccjm.74.3.227
Publikováno v:
Clinical Pharmacokinetics. 46:885-895
To investigate whether the apparent discrepancy between the efficacy of the combination of isosorbide dinitrate (ISDN) and hydralazine demonstrated in the first V-HeFT trial (V-HeFT I) and that in V-HeFT II could be explained by pharmacokinetic diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24a0eddcac11ed8f1f21b0dcae606c6
https://doi.org/10.2165/00003088-200746100-00006
https://doi.org/10.2165/00003088-200746100-00006
Autor:
Joseph A Franciosa
Publikováno v:
Expert Opinion on Pharmacotherapy. 7:2521-2531
The major advances in our understanding and management of heart failure (HF) in recent decades have not fully benefited all segments of our population. HF still represents a growing epidemic, especially for African-Americans, in whom the burden of HF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d89d4f8868b81bb2d24b40995f7863f
https://doi.org/10.1517/14656566.7.18.2521
https://doi.org/10.1517/14656566.7.18.2521
Autor:
M.D. Cheitlin
Publikováno v:
Yearbook of Cardiology. 2008:392-394
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::862e872088156af8592f4abfa9163c32
https://doi.org/10.1016/s0145-4145(08)01044-7
https://doi.org/10.1016/s0145-4145(08)01044-7